Member Info for inanaco

not saying anything ... in here for deals

all about the number you hold ..

and your holding for the same reason .. you can't admit your underwater here then claim you knew 3.6p was coming at 30p etc ..

its codswallop

You have David Evans former chairman .. recognising the importance of who has invested ... paying 7p or 2p over funding round ... because of who its is ...

its all about the Peter Jones and levi Roots moment ..

Money meets good tasty science ...

Knowlesi ... all i have done is exposed your Bazooka .. buy ....

at 3.6p i posted Knowlesi Get in there boy .. spend spend spend ...

instead you Ignored .. (maybe you where busy in a crochet training session)....any you was expecting a funding round at 3p ...............

You have proven yourself wrong ...........

I dont need to say anything ..

chunky ..

https://www.bbc.co.uk/iplayer/episode/b01nln7d/secret-universe-the-hidden-life-of-the-cell

For the record

Wildforce an Inanaco agree

Crumbs posted

I think Inanaco is meaning all late-stage cancers are hard to treat

spot on ...

you refer to pancreatic as more hard to treat that melanoma

all i explained was that is because of """Staging"""

you can twist your posts to suit but you cannot change fact

no he didn't

Crumbs understood what i was posting ...

You did not ...

have a nice day

well you will also hear Lindy describe

Melanoma that has progressed as Dire ...

anyway .. i am not arguing with u on the difficulty of treating ... just your interpretation of "staging"

Ie melanoma is treated early if caught

pancreatic does not present itself until late stage

so i will leave you "thinking" ,,,

and explaining to your followers what you think as correct .. and i will explain with depth, that its NOT ...

ATB

don't worry Tosh loves you

I refer YOU to your own posts

RuckRover
Posts: 2,131
Opinion: No Opinion
Price: 6.25
Proper NumbersToday 13:45Here are some numbers, estimates for 2018 rather than 2019 (USA)

Melanoma - cases 91,270 deaths 9,320
Pancreatic- cases 55,440 deaths 44330

The ratio of deaths to new cases are
Melanoma 10%
Pancreatic 80%

Would this not suggest that pancreatic is "Hard to treat" ?

Now you seem to be back peddling ...

what you are confusing

hard to treat ... with Stage of discovery ...

so like for like .. actually the melanoma numbers are just as high as pancreatic

in other words its the "time available to treat" with pancreatic is so short before death

which is why something like moditope ... may have a chance it turns the most powerful part of the immune system into a killer ...

the CD4 ....

but an immunobody against pancreatic would need to be developed to deliver at a very early stage of the cancers development

but symptoms don't present so you would have to screen for the decease ... MRI etc ..

you may be in the cancer statistics as a patient ...

but in the death statistics from a heart attack

ie the cancer did not kill you ....... it would have done if you had not died of a heart attack

its treatable like melanoma if you catch it early ...

but just like melanoma its a killer if caught late ie the primary lesion has spread its Dire ...

Lindy's words "Dire"

and when you add " I think" into the equation ... the problem is you don't think deep enough

so you then create a question based on death rates ... when actually SCIB1 primary job is adjuvant and mopping up single cancer cells ... not attacking solid tumor that was an unexpected bonus which scancell is now exploiting with check points in the up coming trial ..

so your suggesting flogging it off as a "what ever" product .. when in reality scancell has blind sided you because of immunobody versatility and potency

Moditope cannot treat the adjuvant market

you can have cancer but die of something else

heart failure ...

its how its recorded at time of death ...

An estimated 53,670 new cases of pancreatic cancer (PC) in the US and approximately 43, 0690 will die in 201. Roughly, the incidence is equal in both sexes; however, it is higher in African American than white American.1 It is the fourth most common cause of cancer death after lung, prostate and colorectal cancer, and expected by 2030 to be the second.2 Due to nonspecific symptoms, it is usually presented at advanced stage with less than 10% of patients are potentially candidate to curative surgical resection. Although with this small percentage, there are many obstacles to surgical approach including; a significant morbidity and mortality up to 10% associated with prolonged recovery period and hospital stay. Moreover, approximately 30% of patients do not receive the proper post-operative therapy.3

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176548/

which is why i frame all my posts on valuations around Efficacy

.... the ones you dismiss ...

Ruckrover ... they are all hard to treat ... !!

2019, it is estimated that there will be 96,480 new cases of melanoma in the United States and 7,230 deaths from the disease.

"death"

interesting that the competition has "death" in the numbers

I am happy for you to promote 50p £1.50 ...... go for it ..

all i have said its very difficult to quantify a shareprice ....

but simple market comparison of the value achieved by the check point inhibitors tells you the market can withstand "billions" ....

which is more than 50p or £1.50

he posted it on ADFVN .. its genuine